Keyphrases
A2A Receptor
42%
Adenosine A2A Receptor Antagonist
14%
Anti-inflammatory Effect
14%
Cell Samples
14%
Clinical Efficacy
14%
Hospital Admission
14%
Hypoxia-reoxygenation
14%
Invariant Natural Killer T Cells
100%
Length of Hospital Stay
14%
Lymphocyte Subsets
14%
Opioid Use
14%
Pain Score
14%
Phase II Trial
100%
Placebo
28%
Placebo Groups
14%
Plasma Concentration
14%
Primary Outcome Measure
14%
Randomized Phase II Trial
100%
Randomized Placebo-controlled Trial
14%
Receptor Agonist
42%
Regadenoson
100%
Sickle Cell Disease
100%
T Cell Activation
28%
Tissue Inflammation
14%
Treatment Standards
14%
Vaso-occlusive Crisis
100%
Medicine and Dentistry
Adenosine
14%
Antiinflammatory Activity
14%
Arm
14%
Hypoxia
14%
Infusion
42%
Low Drug Dose
14%
Lymphocyte Subpopulation
14%
Mediator
14%
Natural Killer T Cell
100%
Patient with Sickle Cell Disease
42%
Placebo
57%
Primary Outcome
14%
Receptor
57%
Regadenoson
100%
Sickle-Cell Disease
100%
T Cell Activation
28%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine
16%
Antiinflammatory Activity
16%
Hypoxia
16%
Inflammation
16%
Placebo
66%
Receptor Agonist
66%
Regadenoson
100%
Sickle Cell Anemia
100%
Neuroscience
Adenosine A2A Receptor
14%
Anti-Inflammatory
14%
Blood Plasma
14%
Cell Activation
28%
Lymphocyte Subpopulation
14%
Placebo
57%
Receptor Agonists
57%
Regadenoson
100%
T Cell
100%
Immunology and Microbiology
Agonist
57%
Antiinflammatory Activity
14%
Arm
14%
Blood Level
14%
Low Drug Dose
14%
Lymphocyte Subpopulation
14%
Mediator
14%
Natural Killer T Cell
100%
Reoxygenation
14%
Sickle Cell
100%
T Cell Activation
28%